Muraoka Masashi, Oka Tadayuki, Akamine Shinji, Tagawa Tsutomu, Morinaga Masafumi, Inoue Masao, Yamayoshi Takatomo, Hashizume Satoshi, Matsumoto Keitaro, Hayashi Tomayoshi, Nagayasu Takeshi
Division of Surgical Oncology, Department of Translational Medical Sciences, Nagasaki Graduate School of Biomedical Sciences, Nagasaki, Japan.
J Surg Oncol. 2006 Mar 15;93(4):323-9. doi: 10.1002/jso.20470.
We evaluate the efficacy and safety of the modified intrapleural cisplatin treatment for lung cancer patients with positive pleural lavage cytology or malignant effusion.
The treatment was performed for seven patients with malignant effusion and 18 patents with positive pleural lavage cytology. After pulmonary resection, the pleural cavity was filled with cisplatin with a normal saline solution for 30 min. Complications and survival of the patients were evaluated.
The chest tube duration were significantly prolonged in the treatment (CDDP) group (5.7 +/- 3.6 vs. 2.8 +/- 2.6 days). We had one operative death that developed a bronchial fistula; however, the other complications were not severe. The mortality rate was 4% and the morbidity rate was 60%. We experienced two carcinomatous pleuritis in the CDDP group. The median survival time of the CDDP group was 47.0 +/- 11.1 months and the 3- and 5-year survival rate was 52.6% and 11.3%, respectively.
We were able to perform this treatment for these advanced lung cancer patients, which had the preventive effect of carcinomatous pleuritis. This therapy shows the possibility of a treatment that might lead to an improvement in the prognosis of these patients, without causing severe complications.
我们评估改良胸腔内顺铂治疗对胸腔灌洗细胞学阳性或恶性胸腔积液的肺癌患者的疗效和安全性。
对7例恶性胸腔积液患者和18例胸腔灌洗细胞学阳性患者进行了该治疗。肺切除术后，胸腔内注入顺铂与生理盐水混合液30分钟。评估患者的并发症和生存率。
治疗（顺铂）组的胸管留置时间显著延长（5.7±3.6天对2.8±2.6天）。有1例手术死亡患者发生支气管瘘；然而，其他并发症并不严重。死亡率为4%，发病率为60%。顺铂组出现2例癌性胸膜炎。顺铂组的中位生存时间为47.0±11.1个月，3年和5年生存率分别为52.6%和11.3%。
我们能够对这些晚期肺癌患者进行这种治疗，其对癌性胸膜炎有预防作用。该疗法显示出一种可能改善这些患者预后且不会引起严重并发症的治疗可能性。
